Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Vaprisol
Conivaptan is a dual arginine vasopressin (AVP) receptor antagonist used to treat euvolemic or hypervolemic hyponatremia. It works by blocking the action of AVP at V1A and V2 receptors in the kidneys, which increases water excretion without affecting sodium or potassium levels. This helps to restore normal serum sodium concentration in patients with hyponatremia.
For the treatment of euvolemic or hypervolemic hyponatremia.
Rapid increases in serum sodium with conivaptan can cause osmotic demyelination syndrome. Monitor serum sodium closely and correct sodium levels slowly.
Outcome:
Increased conivaptan levels
Mechanism:
Inhibition of CYP3A4 metabolism
Outcome:
Increased digoxin levels
Mechanism:
Inhibition of P-gp transporter
Outcome:
Decreased conivaptan absorption
Mechanism:
Chelation
Most likely new formulation: Oral extended-release formulation (2025, 60% confidence)
Based on current usage and safety profile, there is a low (5%) likelihood of significant regulatory changes in the next 2 years.
Vasopressin Receptor Antagonist
Benzazepine